β catenin和E cadherin表达预测早期胃癌切除术后复发的临床意义#br# #br#

目的探讨β 连环蛋白（β catenin）和上皮型钙黏蛋白（E cadherin）对早期胃癌（T1～2N0期）患者行根治术后复发的预测价值。 方法选择2012年7月至2014年6月期间在遂宁市中心医院行手术切除的早期胃癌组织样本366例，随访患者复发情况。采用免疫组化染色法检测胃癌组织β catenin和E cadherin表达，及其表达与胃癌临床病理特征的关系。多因素Logistic回归模型分析影响复发的独立危险因素。 结果随访期内共有42例患者复发，复发和未复发患者在病理类型、浸润深度、分化程度、受教育程度以及居住地之间差异存在统计学意义（P＜005）。366例患者中221例β catenin高表达，150例E cadherin高表达，且β catenin和E cadherin表达与浸润深度、分化程度以及复发情况密切相关（P＜005）。多因素Logistic回归分析结果显示，浸润深度、β catenin和E cadherin异常表达是胃癌术后复发的独立因素（P＜005）。复发胃癌患者中β catenin和E cadherin表达无相关性（r=-0033，P=0836）。 结论β catenin和E cadherin表达异常可作为早期胃癌患者术后复发的预测指标，有助于筛选术后复发的高危患者。

Second-line therapy of erlotinib in advanced non-small cell lung cancer

Objective：To evaluate the efficacy and the side effect of erlotinib as the second line therapy in the treatment of patients with advanced non-small cell lung cancer（NSCLC）.Methods：Twenty-eight patients with advanced NSCLC were treated with erlotinib which was given orally as a single drug at a dose of 150mg per day.The efficacy was evaluated according to RECIST criteria and the adverse events were evaluated according to NCI criteria.Results：There was no complete response（CR）,partial response（PR） 17.86%,stable disease（SD） 42. 86% , progressive disease（PD） 39. 28%. The response rate（ CR ＋ PR） was 17.86% , the disease control rate（ CR ＋ PR ＋ SD） was 60. 72% in the 28 cases. Time to progression（TTP） was 2-11 months, and median time to progession （mTYP） was 5.7 months. Median survival time（MST） was 11.5 months. The main side effects were rash and itch of skin, diarrhea and nausea, which could be relieved by treatment. Conclusion：It is effective and feasible to treat advanced NSCLC with erlotinib as the second line therapy.